Science News
from research organizations

Tracing the impact of amyloid beta in mild cognitive impairment

Date:
January 16, 2013
Source:
BioMed Central
Summary:
The amount of amyloid ² (A²) in the brains of people with mild cognitive impairment (MCI) is contributing to early memory loss, and increases with severity of symptoms, finds a new study. The non-invasive study which used 18F-florbetaben to find A² plaques in brain scans to also show that in MCI the affect of A² on memory loss is independent of other aspects of mental decline.
Share:
       
FULL STORY

The amount of amyloid β (Aβ) in the brains of people with mild cognitive impairment (MCI) is contributing to early memory loss, and increases with severity of symptoms, finds a study in BioMed Central’s open access journal Alzheimer's Research & Therapy.
Credit: Kevin Ong, Victor L Villemagne, Alex Bahar-Fuchs, Fiona Lamb, Gaël Chételat, Parnesh Raniga, Rachel S Mulligan, Olivier Salvado, Barbara Putz, Katrin Roth, Colin L Masters, Cornelia B Reininger and Christopher C Rowe

The amount of amyloid β (Aβ) in the brains of people with mild cognitive impairment (MCI) is contributing to early memory loss, and increases with severity of symptoms, finds a study in BioMed Central's open access journal Alzheimer's Research & Therapy. The non-invasive study which used 18F-florbetaben to find Aβ plaques in brain scans to also show that in MCI the affect of Aβ on memory loss is independent of other aspects of mental decline.

Positron emission tomography (PET) has previously relied on carbon-11 labeling of Aβ, however this study uses 18F-florbetaben which can be used for longer and allow more patients to be scanned at lower cost. A higher than normal amount of Aβ was found in half of the PET scans of people with MCI. Interestingly there was a strong association between Aβ and memory loss, but not with other features of neurodegeneration, such as hippocampal atrophy or the white matter hyperintensities frequently seen on MRI later in the development of Alzheimer's disease.

Prof Christopher Rowe, from Austin Health, Australia and the University of Melbourne, who led the study explained why it is important, "MCI is thought to affect between one in five and one in ten of all adults over the age of 65, and, although some of these will go on to develop dementia within a few years, the majority can lead a relatively normal life. Detection of Aβ plaques in MCI indicates early Alzheimer's disease, while a negative scan eliminates this possibility. Consequently a negative scan is very reassuring while a positive scan can lead to earlier and more appropriate medical and social management."


Story Source:

The above post is reprinted from materials provided by BioMed Central. Note: Materials may be edited for content and length.


Journal Reference:

  1. Kevin Ong, Victor L Villemagne, Alex Bahar-Fuchs, Fiona Lamb, Gael Chetelat, Parnesh Raniga, Rachel S Mulligan, Olivier Salvado, Barbara Putz, Katrin Roth, Colin L Masters, Cornelia B Reininger, Christopher C Rowe. 18F-florbetaben Abeta imaging in mild cognitive impairment. Alzheimer's Research & Therapy, 2013; 5 (1): 4 DOI: 10.1186/alzrt158

Cite This Page:

BioMed Central. "Tracing the impact of amyloid beta in mild cognitive impairment." ScienceDaily. ScienceDaily, 16 January 2013. <www.sciencedaily.com/releases/2013/01/130116091453.htm>.
BioMed Central. (2013, January 16). Tracing the impact of amyloid beta in mild cognitive impairment. ScienceDaily. Retrieved August 5, 2015 from www.sciencedaily.com/releases/2013/01/130116091453.htm
BioMed Central. "Tracing the impact of amyloid beta in mild cognitive impairment." ScienceDaily. www.sciencedaily.com/releases/2013/01/130116091453.htm (accessed August 5, 2015).

Share This Page: